The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment
Titel:
The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment
Auteur:
Ariceta, Gema Dixon, Bradley P. Kim, Seong Heon Kapur, Gaurav Mauch, Teri Ortiz, Stephan Vallee, Marc Denker, Andrew E. Kang, Hee Gyung Greenbaum, Larry A.